Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Whitehawk Therapeutics, Inc. (WHWK : NSDQ)

• Company Description    Aadi Bioscience Inc. is a clinical-stage biopharmaceutical company. It focuses on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes. Aadi Bioscience Inc., formerly known as Aerpio Pharmaceuticals Inc., is based in LOS ANGELES. Number of Employees: 40

• Price / Volume Information    Yesterday's Closing Price: $2.07 Daily Weekly Monthly 20 Day Moving Average: 5,223,474 shares Shares Outstanding: 47.13 (millions) Market Capitalization: $97.56 (millions) Beta: 0.58 52 Week High: $3.81 52 Week Low: $1.39 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 2.48% -0.21% 12 Week 29.38% 24.01% Year To Date -34.39% -42.65%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2 HEADQUARTERS PLAZA EAST BUILDING 11TH FLOOR - MORRISTOWN,NJ 7960 USA ph: 551-321-2234 fax: - ir@whitehawktx.com https://ir.whitehawktx.com

• General Corporate Information    Officers David J. Lennon - Chief Executive Officer and President Caley Castelein - Chairman Scott Giacobello - Chief Financial Officer Anupam Dalal - Director Neil Desai - Director Peer Information Whitehawk Therapeutics, Inc. (CORR.) Whitehawk Therapeutics, Inc. (RSPI) Whitehawk Therapeutics, Inc. (CGXP) Whitehawk Therapeutics, Inc. (BGEN) Whitehawk Therapeutics, Inc. (GTBP) Whitehawk Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00032Q104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/17/26 Share - Related Items Shares Outstanding: 47.13 Most Recent Split Date: 8.00 (0.07:1) Beta: 0.58 Market Capitalization: $97.56 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.27 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.45 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/17/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.62 Price/Cash Flow: - Price / Sales: 3.51 EPS Growth vs. Year Ago Period: 43.48% vs. Previous Quarter: 65.79% Sales Growth vs. Year Ago Period: 33.48% vs. Previous Quarter: -1.30% ROE 09/30/25 - -68.32 06/30/25 - -75.99 03/31/25 - -56.73 ROA 09/30/25 - -63.21 06/30/25 - -68.57 03/31/25 - -48.68 Current Ratio 09/30/25 - 16.76 06/30/25 - 20.41 03/31/25 - 18.95 Quick Ratio 09/30/25 - 16.76 06/30/25 - 20.41 03/31/25 - 18.95 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - -215.41 Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - 99.42 Pre-Tax Margin 09/30/25 - -108.58 06/30/25 - -48.24 03/31/25 - 99.42 Book Value 09/30/25 - 3.33 06/30/25 - 3.65 03/31/25 - 4.74 Inventory Turnover 09/30/25 - 1.17 06/30/25 - 0.87 03/31/25 - 0.74 Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©